{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:17:32Z","timestamp":1787977052709,"version":"build-2784847793"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7688-26","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:12:01Z","timestamp":1787609521000},"source":"Crossref","is-referenced-by-count":0,"title":["Hemophagocytic Lymphohistiocytosis as a Clinical Harbinger of Rapid Disease Progression in Multiple Myeloma During Daratumumab-Based Therapy"],"prefix":"10.2169","author":[{"given":"Hisaharu","family":"Shikata","sequence":"first","affiliation":[{"name":"Department of Hematology, Uwajima City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Hematology, Uwajima City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Matsukage","sequence":"additional","affiliation":[{"name":"Department of Pathology, Uwajima City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol 172: 412-419, 2016.","DOI":"10.1111\/bjh.13837"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet 383: 1503-1516, 2014.","DOI":"10.1016\/S0140-6736(13)61048-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Setiadi A, Zoref-Lorenz A, Lee CY, Jordan MB, Chen LYC. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol 9: e217-e227, 2022.","DOI":"10.1016\/S2352-3026(21)00366-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380: 2104-2115, 2019.","DOI":"10.1056\/NEJMoa1817249"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med 31: 1195-1202, 2025.","DOI":"10.1038\/s41591-024-03485-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 391: 1597-1609, 2024.","DOI":"10.1056\/NEJMoa2400712"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Patir P, Kurtoglu E. Ruxolitinib for hemophagocytic lymphohistiocytosis in multiple myeloma: case report and review of the literature. Clin Lab 71: 170-174, 2025.","DOI":"10.7754\/Clin.Lab.2024.240810"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bunting ST, Baljevic M. Secondary hemophagocytic histiocytosis arising from newly diagnosed multiple myeloma. Annals of Case Reports 10: 2465, 2025.","DOI":"10.29011\/2574-7754.102465"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hsu CM, Bennett JM, Lipe B. Hemophagocytic lymphohistiocytosis in a patient with multiple myeloma. Clin Lymphoma Myeloma Leuk : e29-e32, 2019.","DOI":"10.1016\/j.clml.2018.08.017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Woods A, Wooten M, Thompson Heffner LT Jr, Waller E. Daratumumab-associated hemophagocytic lymphohistiocytosis. Ann Hematol 99: 181-182, 2020.","DOI":"10.1007\/s00277-019-03877-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Runge E, Kou CJ, Rendo M, Lynch D, Fenderson J. Lenalidomide-associated hemophagocytic lymphohistiocytosis with plasma cell phagocytosis. Cureus 13: e14409, 2021.","DOI":"10.7759\/cureus.14409"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ostronoff M, Ostronoff F, Coutinho M, et al. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma: successful treatment with high-dose intravenous immunoglobulin. Bone Marrow Transplant 37: 797-798, 2006.","DOI":"10.1038\/sj.bmt.1705329"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yan W, Xiong Y, Lv R, et al. Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report. J Immunother Cancer 12: e010080, 2024.","DOI":"10.1136\/jitc-2024-010080"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gars E, Purington N, Scott G, et al. Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis. Haematologica 103: 1635-1641, 2018.","DOI":"10.3324\/haematol.2017.186627"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Henter JI, Sieni E, Eriksson J, et al. Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited. Blood 144: 2308-2318, 2024.","DOI":"10.1182\/blood.2024025077"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the Hscore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66: 2613-2620, 2014.","DOI":"10.1002\/art.38690"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yoshida M, Morita K, Fukushima H, et al. Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma. Int J Hematol 117: 769-773, 2023.","DOI":"10.1007\/s12185-022-03499-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Saltarella I, Desantis V, Melaccio A, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells 9: 167, 2020.","DOI":"10.3390\/cells9010167"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Viola D, Dona A, Caserta E, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia 35: 189-200, 2021.","DOI":"10.1038\/s41375-020-0810-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Murdaca G, Allegra A, Paladin F, Calapai F, Musolino C, Gangemi S. Involvement of alarmins in the pathogenesis and progression of multiple myeloma. Int J Mol Sci 22: 9039, 2021.","DOI":"10.3390\/ijms22169039"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128: 384-394, 2016.","DOI":"10.1182\/blood-2015-12-687749"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7688-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:31:43Z","timestamp":1787974303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7688-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7688-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7688-26"}}